The Mark Foundation for Cancer Research
TXBT and Beyond ASPIRE Awards
Last seen in a scan/import: .
Catalog updated: .
These timestamps are not source verification. Confirm the current deadline and your eligibility on the funder’s call page before applying.
No deadline is on file for this call. Check The Mark Foundation for Cancer Research's own call page for the current round's status before you plan around it.
The TXBT and Beyond ASPIRE Awards, a joint RFP from the Mark Foundation for Cancer Research and the Chordoma Foundation, fund research developing new strategies that target the chordoma surfaceome. Independent researchers worldwide can apply for ASPIRE I (up to $250,000 over 12 months) or ASPIRE II (up to $750,000 over 36 months), covering basic, translational, technology, or clinical research, with clinical studies capped at $500,000.
Details
| Funder | The Mark Foundation for Cancer Research |
| Budget | Up to $250,000 (ASPIRE I) or up to $750,000 (ASPIRE II); up to $500,000 for clinical studies |
| Duration | Up to 12 months (ASPIRE I) or up to 36 months (ASPIRE II) |
| Consortium | Optional — collaborations are within the scope of the funding mechanism; co-investigators are permitted |
Eligibility & scope
Joint RFP with the Chordoma Foundation to accelerate development of new strategies targeting the chordoma surfaceome. Open to independent researchers worldwide; supports basic, translational, technology, or clinical research projects.
Who Should Apply
- •Independent researchers worldwide, any career stage
- •Labs working on chordoma or surfaceome-targeting strategies
- •Basic, translational, technology, or clinical research projects
- •Teams proposing clinical studies (capped at $500,000)
- •Applicants open to optional collaborations or co-investigators
Key Dates
- •Two funding tracks: ASPIRE I (up to 12 months) and ASPIRE II (up to 36 months)
Tips for Applicants
- ✓Frame the project explicitly around the chordoma surfaceome, this is a joint RFP with the Chordoma Foundation, so proposals outside that focus are a poor fit.
- ✓Match project scope to track: ASPIRE I suits shorter, focused studies while ASPIRE II supports multi-year programs including clinical work.
- ✓If proposing a clinical study, note the $500,000 cap explicitly in your budget justification since it differs from the general ASPIRE II ceiling.
Frequently Asked Questions
How much funding does the ASPIRE Award provide?
ASPIRE I awards up to $250,000 over 12 months, ASPIRE II awards up to $750,000 over 36 months, and clinical studies are capped at $500,000.
Who is eligible for the TXBT and Beyond ASPIRE Awards?
Independent researchers anywhere in the world working on chordoma surfaceome-targeting strategies are eligible.
What type of research does this grant fund?
It funds basic, translational, technology, or clinical research aimed at new strategies targeting the chordoma surfaceome.
Is collaboration required for the ASPIRE Awards?
No, collaborations and co-investigators are optional and permitted but not required.
Summary generated by AI based on published grant information. Always verify details on the funder's website.
Similar grants
Aspire Award
The Mark Foundation for Cancer ResearchUp to $250k (ASPIRE I, up to $500k for clinical studies) or up to $750k (ASPIRE II)Therapeutic Catalyst - Target Award
Cancer Research UKDeadline: 5 Feb 2027Up to £250KImpact Grant
Cancer Research InstituteDeadline: 1 Dec 2026$300,000Therapeutic Catalyst - Early Therapy Award
Cancer Research UKDeadline: 5 Feb 2027Up to £350KChildhood Cancer Therapeutic Catalyst
Cancer Research UKUp to £250k
Could TXBT and Beyond ASPIRE Awards be right for you?
See your personalised match score for this grant and others in 30 seconds. No signup needed to preview.
See my matches free →